Media Room

Stefanie Kutschmann, Good Manufacturing Practice Officer, Frankfurt, Germany

First quarter 2024 results

First quarter 2024 results will be reviewed by management during a conference call with the financial community on April 25th. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EST)

Press releases

April 17, 2024
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
March 22, 2024
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
March 11, 2024
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

Contact our media team

You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.

For any other request, please call the switchboard: +33 1 53 77 40 00


Declaration of extra-financial performance 2023 (ESG Report)
Download PDF
Half Year 2023 Financial Report XBRL Package
Download PDF
Half Year 2023 Financial Report
Download PDF
First quarter 2023 results
Download PDF